| Business Summary | | Alteon
Inc.
is
a
product-based
biopharmaceutical
company
engaged
in
the
discovery
and
development
of
oral
drugs
for
the
treatment
of
diseases
of
aging
and
diabetes.
The
Company's
product
candidates
represent
novel
approaches
to
some
of
the
largest
pharmaceutical
markets,
such
as
cardiovascular
and
kidney
diseases.
Two
of
the
Company's
compounds
are
in
clinical
development;
several
others
are
undergoing
pre-clinical
testing.
These
pharmaceutical
candidates
were
developed
as
a
result
of
the
Company's
understanding
of
the
Advanced
Glycosylation
End-product
(A.G.E.)
pathway,
a
fundamental
pathological
process
and
inevitable
consequence
of
aging
that
may
result
in
many
medical
disorders. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Alteon
Inc.
is
engaged
in
the
discovery
and
development
of
new
pharmaceutical
products
for
the
treatment
of
cardiovascular
and
renal
diseases
and
other
disorders
of
diabetes
and
aging.
For
the
six
months
ended
6/30/01,
revenues
fell
18%
to
$253
thousand.
Net
loss
applicable
to
Common
rose
25%
to
$7.9
million.
Revenues
suffered
from
a
decrease
in
cash,
cash
equivalents
and
short
term
investment
balances.
Higher
loss
also
reflects
increased
personnel
and
R
and
D
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Kenneth Moch, 46 Chairman,
Pres, CEO | $410K | $6.6K | Robert DeGroof, Ph.D., 56 Sr.
VP, Scientific Affairs | 189K | -- | Elizabeth O' Dell, 40 VP
of Fin. and Admin., Sec., Treasurer | 145K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|